Latest Breaking News On - புற்றுநோயியல் இல் யேல் புற்றுநோய் மையம் - Page 1 : comparemela.com

Epidermal growth factor receptor ( EGFR) mutations are seen in approximately 10-20% of patients with non-small cell lung cancer (NSCLC), with a higher percentage observed among Asian patients. But considering that over 200,000 people a year are diagnosed with lung cancer, that seemingly small percentage represents a lot of patients, said Roy Herbst, MD, PhD, chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut. Over the past 2 decades, tyrosine kinase inhibitors (TKIs) targeting EGFR have emerged, beginning with the two first-generation EGFR-TKIs, gefitinib (Iressa) and erlotinib (Tarceva). A series of trials evaluating first- and second-generation EGFR TKIs found that erlotinib, gefitinib, and afatinib (Gilotrif) were the best first-line treatment options for patients with advanced NSCLC with

New havenUnited statesRoy herbstOncology at yale cancer centerAmerican society of clinical oncologyData monitoring committeeMedical oncologyYale cancer centerSmilow cancer hospitalIndependent data monitoring committeeClinical oncologyNon small cell lung cancerSecondary malignant neoplasm of brainSecondary malignant neoplasm of brain and spinal cordMalignant tumor of lungபுதியது புகலிடம்